Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.43%
#2 Audiera Audiera +17.52%
#3 Geodnet Geodnet +15.92%
#4 Ocean Protocol Ocean Protocol +14.50%
#5 DexNet DexNet +7.78%
#6 Cysic Cysic +7.25%
#7 Arowana Arowana +6.31%
#8 The Bitcoin Bull The Bitcoin Bull +6.31%
#9 Rollbit Coin Rollbit Coin +6.30%
#10 Bityuan Bityuan +4.86%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Classement en actions #32330
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Prix de l'action
$0.88
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$10.41M
Changement (1 jour)
-7.26%
Changement (1 an)
-50.56%
Pays
SG
Échange CytoMed Therapeutics Limited (GDTC)

Catégorie

Healthcare
Ratio P/B pour CytoMed Therapeutics Limited (GDTC)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de CytoMed Therapeutics Limited, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour CytoMed Therapeutics Limited de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR